AKBA

Akebia Therapeutics Inc

0.5853

Oct 21 • 3:59 PM ET -0.0328 (-5.31%)

0.6180

Aftermarket • 7:59 PM ET +0.0327 (5.59%)

Healthcare Drug Manufacturers - Specialty & Generic USA Micro NASD

Peers: ARDX UNCY RMTI AMGN GSK OPK PROK TVTX VERA DVA

| Held by: VTI IWM VXF VTWO IWO FESM SCHA VHT IWC SMLF

Scroll to Statements

Index	RUT
Market Cap	162.19M
Enterprise Value	215.74M
Income	-29.67M
Sales	219.06M
Book/sh	0.09
Cash/sh	0.57
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	194
IPO	Mar 20, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	0.74
P/B	6.36
P/C	1.03
P/FCF	4.03
EV/EBITDA	-
EV/Sales	0.98
Quick Ratio	1.35
Current Ratio	1.43
Debt/Eq	8.43
LT Debt/Eq	6.44
Option/Short	Yes / Yes

EPS (ttm)	-0.11
EPS next Y	-0.30
EPS next Q	-0.04
EPS this Y	-600.58%
EPS next Y	-117.39%
EPS next 5Y	-
EPS past 3/5Y	65.70% 62.40%
Sales past 3/5Y	-6.88% -4.37%
EPS Y/Y TTM	35.69%
Sales Y/Y TTM	7.52%
EPS Q/Q	-3766.67%
Sales Q/Q	-21.36%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	28.57% 0.56%

Insider Own	2.71%
Insider Trans	-0.74%
Inst Own	40.50%
Inst Trans	3.45%
ROA	-8.53%
ROE	-109.38%
ROIC	-15.93%
Gross Margin	78.92%
Oper. Margin	-6.02%
Profit Margin	-13.54%
SMA20	-27.02%
SMA50	-33.20%
SMA200	-50.17%
Trades

Shs Outstand	271.74M
Shs Float	269.58M
Short Float	8.34%
Short Ratio	3.29
Short Interest	22.48M
52W High	3.20 -81.71%
52W Low	0.61 -4.30%
Volatility	9.47% 6.31%
ATR (14)	0.05
RSI (14)	21.14
Beta	0.20
Rel Volume	2.86
Avg Volume	6.83M
Volume	19,537,550

Perf Week	-16.62%
Perf Month	-40.28%
Perf Quarter	-52.02%
Perf Half Y	-58.78%
Perf YTD	-63.65%
Perf Year	-81.24%
Perf 3Y	-29.47%
Perf 5Y	-79.82%
Perf 10Y	-92.77%
Recom	1.33
Target Price	3.92
Prev Close	0.62
Price	0.59
Change %	-5.31%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-07-26	Downgrade	Leerink Partners	Outperform → Market Perform	$1
Jun-04-25	Resumed	H.C. Wainwright	Buy	$8
Apr-28-25	Initiated	Leerink Partners	Outperform	$7
Apr-01-25	Initiated	Jefferies	Buy	$6
Nov-29-23	Resumed	BTIG Research	Buy	$4
Aug-28-23	Upgrade	H.C. Wainwright	Neutral → Buy	$3.75
May-31-23	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $4
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral	$8 → $2
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Mizuho	Buy → Neutral	$6 → $2
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $2
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight	$8
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy	$18 → $15
Aug-06-19	Reiterated	H.C. Wainwright	Buy	$19 → $17
Jul-11-19	Reiterated	H.C. Wainwright	Buy	$23 → $21
May-02-19	Initiated	JP Morgan	Overweight	$12
Mar-20-19	Initiated	Citigroup	Neutral	$9
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy	$20 → $18

Show Previous Ratings

Oct-07-26 08:00AM	Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum (GlobeNewswire)
Oct-06-26 08:00AM	Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026 (GlobeNewswire)
Oct-01-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.33%
Sep-14-26 08:00AM	Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases (GlobeNewswire)
Sep-01-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
08:00AM	Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston (GlobeNewswire)
Aug-06-26 01:10AM	Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ... (GuruFocus.com) -26.02%
Aug-05-26 05:04PM	Akebia Therapeutics: Q2 Earnings Snapshot (Associated Press)
04:05PM	Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
Aug-03-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases (GlobeNewswire)
Jul-29-26 08:00AM	Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Jul-02-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-26 08:00AM	U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA (GlobeNewswire)
Jun-10-26 08:00AM	Akebia Therapeutics Strengthens Vafseo (vadadustat) Patent Portfolio (GlobeNewswire) -5.12%
04:05PM	Loading…
Jun-01-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.20%
May-28-26 08:00AM	Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-07-26 07:10AM	Akebia Therapeutics: Q1 Earnings Snapshot (Associated Press) -20.27%
07:00AM	Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights (GlobeNewswire)
May-04-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.14%
08:00AM	Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology (GlobeNewswire)
Apr-30-26 04:05PM	Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Apr-13-26 08:00AM	Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 (GlobeNewswire) +5.00%
Apr-07-26 08:00AM	Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium (GlobeNewswire)
Apr-02-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-26 04:05PM	Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors (GlobeNewswire)
Mar-19-26 04:05PM	Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 (GlobeNewswire)
Mar-03-26 08:00AM	Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
Mar-02-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-26 08:30AM	Akebia Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
04:14PM	Loading…
Feb-26-26 04:14PM	Akebia Therapeutics Inc (AKBA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com) +9.09%
09:16AM	Akebia Therapeutics Q4 Earnings Call Highlights (MarketBeat)
07:30AM	Akebia Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights (GlobeNewswire)
Feb-19-26 07:28PM	Piper Sandler Lowers Akebia Therapeutics (AKBA) PT to $4 as Firm Updates Estimates Following Year-End Reports (Insider Monkey)
05:10PM	Ardelyx (ARDX) Reports Break-Even Earnings for Q4 (Zacks)
08:00AM	Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Feb-12-26 10:34AM	Akebia Therapeutics Spotlights VAFSEO Dialysis Push, TIW Dosing Plan and Rare Kidney Pipeline at Summit (MarketBeat) -12.26%
Feb-04-26 08:00AM	Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Feb-02-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-12-26 08:00AM	Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook (GlobeNewswire) -7.89%
Jan-07-26 08:22AM	Akebia announces first patient dosed in Phase 2 trial of praliciguat (TipRanks)
Jan-06-26 08:00AM	Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) (GlobeNewswire)
Jan-05-26 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-28-25 12:46PM	Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat (Insider Monkey)
Dec-02-25 11:28AM	This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? (Barchart)
Dec-01-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Q32 Bio Sells Complement Inhibitor ADX-097 (PR Newswire)
07:00AM	Akebia Announces Establishment of Rare Kidney Disease Pipeline (GlobeNewswire)
Nov-24-25 08:00AM	Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 11:01AM	Implied Volatility Surging for Akebia Therapeutics Stock Options (Zacks)
Nov-11-25 10:10AM	Theravance's Q3 Earnings Surpass Estimates, Revenues Match (Zacks) +8.38%
09:35AM	Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-10-25 02:01PM	Akebia Therapeutics Inc (AKBA) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) -18.14%
07:00AM	Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-07-25 12:51PM	Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y (Zacks)
Nov-06-25 06:55PM	Globus Medical (GMED) Tops Q3 Earnings and Revenue Estimates (Zacks) -5.19%
06:30PM	Vafseo (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs (GlobeNewswire)
Nov-05-25 05:50PM	Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 08:00AM	Akebia Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-25 08:00AM	Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Oct-28-25 04:30PM	Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients (GlobeNewswire) -32.04%
Oct-20-25 08:08AM	Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025 (GlobeNewswire) +7.85%
Oct-15-25 06:19AM	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks) +5.73%
Oct-14-25 10:57AM	5 Small Drug Stocks to Buy as the Industry Shows Some Recovery (Zacks)
Oct-08-25 09:40AM	Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-01-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-24-25 03:48AM	Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last? (Zacks)
Sep-02-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-25 08:00AM	Akebia Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-21-25 08:00AM	Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo (vadadustat) Across All IRC Dialysis Clinics (GlobeNewswire)
Aug-20-25 12:22AM	Akebia Therapeutics (AKBA) Bounces to Profitability amid Kidney Treatment Growth (Insider Monkey)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -20.48%
08:25AM	Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2 (Zacks)
07:00AM	Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-06-25 06:15PM	OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference (GlobeNewswire)
Aug-04-25 08:00AM	Akebia Initiates Vafseo (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization (GlobeNewswire)
Aug-01-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:40AM	Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year? (Zacks)
Jul-31-25 08:00AM	Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights (GlobeNewswire)
Jul-25-25 12:09PM	H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy (Insider Monkey) -7.29%
Jul-22-25 11:03AM	Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share (Insider Monkey)
Jul-16-25 12:00PM	Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
09:40AM	Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-08-25 08:00AM	Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference (GlobeNewswire)
Jul-07-25 09:10AM	Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT (Insider Monkey)
Jul-02-25 10:08PM	Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase (Insider Monkey)
Jul-01-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:42AM	Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials (Insider Monkey)
Jun-17-25 09:53AM	Averoa secures EC authorisation for oral CKD treatment (Pharmaceutical Technology)
Jun-04-25 08:00AM	Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology (GlobeNewswire) +6.43%
Jun-02-25 04:05PM	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.26% +5.23%
May-28-25 08:00AM	Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-27-25 08:00AM	Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025 (GlobeNewswire)
May-13-25 08:00AM	Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-09-25 03:11AM	Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... (GuruFocus.com)
May-08-25 08:15AM	Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates (Zacks) +6.50%
07:18AM	Akebia Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Butler John P.	CEO and President	Aug 06 '26	Option Exercise	0.63	350,000	220,500	3,718,564	Aug 10 04:08 PM
Ostrowski Erik	SVP, CFO, CBO & Treasurer	Jun 29 '26	Sale	1.11	56,019	62,181	616,616	Jul 01 04:34 PM
Ostrowski Erik	Officer	Jun 29 '26	Proposed Sale	1.11	56,019	62,220		Jun 29 08:38 PM
Butler John P.	CEO and President	Mar 04 '26	Buy	1.25	69,270	86,588	3,367,064	Mar 05 06:55 PM
Malabre Richard C	SVP, Chief Accounting Officer	Feb 02 '26	Sale	1.39	49,524	68,838	299,390	Feb 04 04:15 PM
Grund Nicholas	Chief Commercial Officer	Feb 02 '26	Sale	1.39	84,829	117,912	561,750	Feb 04 04:13 PM
Burke Steven Keith	SVP, Chief Medical Officer	Feb 02 '26	Sale	1.39	67,658	94,045	948,432	Feb 04 04:13 PM
Rucci Carolyn M.	SVP, Chief Legal Officer	Feb 02 '26	Sale	1.39	69,772	96,983	588,378	Feb 04 04:12 PM
Ostrowski Erik	SVP, CFO, CBO & Treasurer	Feb 02 '26	Sale	1.39	34,951	48,582	672,635	Feb 04 04:11 PM
Butler John P.	CEO and President	Feb 02 '26	Sale	1.39	341,305	474,414	3,206,233	Feb 04 04:10 PM
Ostrowski Erik	Officer	Feb 02 '26	Proposed Sale	1.39	34,951	48,739		Feb 02 05:58 PM
Grund Nicholas	Officer	Feb 02 '26	Proposed Sale	1.39	84,829	118,294		Feb 02 05:57 PM
Burke Steven Keith	Officer	Feb 02 '26	Proposed Sale	1.39	67,658	94,349		Feb 02 05:55 PM
Butler John P.	Officer	Feb 02 '26	Proposed Sale	1.39	341,305	475,950		Feb 02 05:54 PM
Rucci Carolyn M.	Officer	Feb 02 '26	Proposed Sale	1.39	69,772	97,297		Feb 02 05:52 PM

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice Jr., Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

CEOMr. John P. Butler MBA

Chief Business OfficerMr. Erik John Ostrowski M.B.A.

Senior VP and Chief Research & Development OfficerDr. Steven Keith Burke M.D.

Senior VP & Chief Commercial OfficerMr. Nicholas Grund

Senior VP & Chief Accounting OfficerMr. Richard C. Malabre

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKBA

Akebia Therapeutics Inc

Upgrade your Finviz experience